Skip to main content
SpringerLink
Log in

Take an individualised approach when treating frail, elderly patients with nocturia

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Nocturia is a complex symptom that is attributed to a wide range of causes, including advanced age, comorbidities and medications. Non-pharmacological treatments are first-line options in the management of nocturia in frail, elderly patients due to their safety in this vulnerable population. If pharmacotherapy is required, the benefits must be carefully weighed against the potential for adverse effects. Desmopressin, α-antagonists, antimuscarinic drugs and β3‑adrenergic agonists have been identified as potential pharmacological options, though the evidence for their use in frail, elderly patients is limited.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wolff DT, Adler KA, Weinstein CS, et al. Managing nocturia in frail older adults. Drugs Aging. 2020;38(2):95–109.

    Article  Google Scholar 

  2. Shaw C, Wagg A. Urinary and faecal incontinence in older adults. Medicine. 2021;49(1):44–50.

    Article  Google Scholar 

  3. Shaw C, Wagg A. Overactive bladder in frail older adults. Drugs Aging. 2020;37(8):559–65.

    Article  CAS  Google Scholar 

  4. Everaert K, Hervé F, Bosch R, et al. International Continence Society consensus on the diagnosis and treatment of nocturia. Neurourol Urodyn. 2019;38(2):478–98.

    Article  Google Scholar 

  5. US National Library of Medicine. DailyMed: US prescribing information. 2021. https://dailymed.nlm.nih.gov/. Accessed 29 Apr 2021.

  6. American Geriatrics Society Beers Criteria® Update Expert Panel. Updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–94.

  7. Sakalis VI, Karavitakis M, Bedretdinova D, et al. Medical treatment of nocturia in men with lower urinary tract symptoms: systematic review by the European Association of Urology Guidelines Panel for male lower urinary tract symptoms. Eur Urol. 2017;72(5):757–69.

    Article  Google Scholar 

  8. Kaminetsky J, Fein S, Dmochowski R, et al. Efficacy and safety of SER120 nasal spray in patients with nocturia: pooled analysis of 2 randomized, double-blind, placebo controlled, phase 3 trials. J Urol. 2018;200(3):604–11.

    Article  CAS  Google Scholar 

  9. Johnson TM, Burrows PK, Kusek JW, et al. The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol. 2007;178(5):2045–50.

    Article  CAS  Google Scholar 

  10. Eisenhardt A, Schneider T, Cruz F, et al. Consistent and significant improvement of nighttime voiding frequency (nocturia) with silodosin in men with LUTS suggestive of BPH: pooled analysis of three randomized, placebo-controlled, double-blind phase III studies. World J Urol. 2014;32(5):1119–25.

    Article  Google Scholar 

  11. Chapple CR, Montorsi F, Tammela TLJ, et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011;59(3):342–52.

    Article  CAS  Google Scholar 

  12. Kim SO, Choi HS, Kwon D. The α1 adrenoceptor antagonist tamsulosin for the treatment of voiding symptoms improves nocturia and sleep quality in women. Urol J. 2014;11(3):1636–41.

    PubMed  Google Scholar 

  13. DuBeau CE, Kraus SR, Griebling TL, et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind. Placebo controlled trial. J Urol. 2014;191(2):395–404.

    Article  CAS  Google Scholar 

  14. Lee YK, Kuo HC. Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities. Geriatr Gerontol Int. 2018;18(9):1330–3.

    Article  Google Scholar 

  15. Sebastianelli A, Russo GI, Kaplan SA, et al. Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: comparison with placebo and tolterodine. Int J Urol. 2018;25(3):196–205.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand

    Arnold Lee

Authors
  1. Arnold Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arnold Lee.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and conflict of interest

A. Lee is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability

Not applicable.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, A. Take an individualised approach when treating frail, elderly patients with nocturia. Drugs Ther Perspect 37, 354–357 (2021). https://doi.org/10.1007/s40267-021-00850-1

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-021-00850-1

Search

Navigation